Shuttle Pharmaceuticals Inc (SHPH) - Total Liabilities
Based on the latest financial reports, Shuttle Pharmaceuticals Inc (SHPH) has total liabilities worth $8.46 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Shuttle Pharmaceuticals Inc - Total Liabilities Trend (2017–2025)
This chart illustrates how Shuttle Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. See Shuttle Pharmaceuticals Inc current assets vs equity to evaluate short-term liquidity relative to the company's equity base.
Shuttle Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Shuttle Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sino-German United AG
F:SGU
|
Germany | €1.03 Million |
|
Arecor Therapeutics PLC
LSE:AREC
|
UK | GBX1.65 Million |
|
Elixxer Ltd
V:ELXR
|
Canada | CA$17.22 Million |
|
Altair Resources Inc
V:AVX
|
Canada | CA$3.11 Million |
|
Annum Bhd
KLSE:5082
|
Malaysia | RM20.48 Million |
|
Shoe Zone PLC
LSE:SHOE
|
UK | GBX54.78 Million |
|
Lytus Technologies Holdings PTV. Ltd. Common Shares
NASDAQ:LYT
|
USA | $15.24 Million |
|
Exploitasi Energi Indonesia
JK:CNKO
|
Indonesia | Rp2.02 Trillion |
Liability Composition Analysis (2017–2025)
This chart breaks down Shuttle Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see SHPH market cap overview.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.53 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.72 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Shuttle Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Shuttle Pharmaceuticals Inc (2017–2025)
The table below shows the annual total liabilities of Shuttle Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $8.22 Million | +357.48% |
| 2024-12-31 | $1.80 Million | -5.21% |
| 2023-12-31 | $1.90 Million | +94.32% |
| 2022-12-31 | $975.68K | -57.20% |
| 2021-12-31 | $2.28 Million | +2.03% |
| 2020-12-31 | $2.23 Million | +276.27% |
| 2018-12-31 | $593.82K | +46.39% |
| 2017-12-31 | $405.65K | -- |
About Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.